Alternative pre-mRNA splicing is an important element in eukaryotic gene expression, as most of the protein-coding genes use this process to generate multiple protein isoforms from a single gene. An increasing number of human diseases are now recognized to be caused by the selection of 'wrong' alternative exons. Research during the last few years identified a number of low-molecular-mass chemical substances that can change alternative exon usage. Most of these substances act by either blocking histone deacetylases or by interfering with the phosphorylation of splicing factors. How the remaining large number of these substances affect splicing is not yet fully understood. The emergence of these low-molecular-mass substances provides not only probes for studying alternative pre-mRNA splicing, but also opens the door to the possible harnessing of these compounds as drugs to control diseases caused by the selection of 'wrong' splice sites.
sex determination in Drosophila [4] and certain apoptotic events [5] . The potential of alternative pre-mRNA splicing to increase the number of proteins generated from a single gene demonstrates that alternative pre-mRNA splicing is a central element of eukaryotic gene regulation and explains why it has been selected during evolution.
The recognition of exons in the pre-mRNA is a dynamic process that is coupled with transcription and other premRNA processing steps, such as 5 -end capping, 3 -end processing, polyadenylation and editing. Since the sequences of the splice sites that surround exons are highly degenerate, additional sequences on the pre-mRNA aid in exon recognition. The interplay between these sequences on the pre-mRNA and more than 300 proteins (reviewed in [6] ) that have been identified in MS analyses leads ultimately to the recognition of the splice sites by the spliceosome and the joining of exons [7] .
The recognition of alternative exons is frequently subjected to regulation. The utilization of an alternative exon depends on the cell type, the developmental stage and/or the reception of cellular signals (reviewed in [8] [9] [10] ). These changes can occur within 1 h in animal systems [11] , and in most systems studied, these changes do not involve de novo protein synthesis [8] . Post-translational modifications of splicing factors, such as phosphorylation (reviewed in [12] ), glycosylation [13] , acetylation [14] or methylation [15] , also play key roles in the regulation of splice-site selection. The importance of proper splice site recognition is apparent from the growing number of human diseases that are recognized to be caused by the selection of incorrect splice sites [16, 17] . These diseases result from either mutations, as in the case of FTDP-17 (frontotemporal dementia and parkinsonism linked to chromosome 17) and Duchenne's muscular dystrophy, or deregulation of the cellular splicing machinery, as exemplified by the numerous changes in alternative splicing seen in cancer [18] . Alternative splicing has therefore rapidly emerged as a new drug target [19] , especially since protein isoforms generated by this process can have different pharmacological effects [20] . The unexpected alteration of alternative splice-site selection may also explain the side effects that established drugs have in addition to their principal role.
Given the importance of alternative splicing, it is surprising that no low-molecular-mass compounds have been identified that specifically inhibit certain splicing events or stages in the splicing reaction. The use of RNA-binding molecules as antibiotics, such as gentamicin, chloramphenicol and tetracycline, certainly illustrates that drugs can be targeted against RNA and/or RNA-binding proteins.
The lack of compounds for the activation or inhibition of specific pre-mRNA splicing events is a problem for studying the splicing reaction itself and for the generation of therapeutic approaches to treat diseases caused by missplicing. During the last 5 years, research focused on changing incorrect splice-site selection to the desired outcome led to the identification of several low-molecular-mass components, which are the subject of the present review. So far, the common feature of these compounds is the low degree of specificity with which they affect numerous splicing events.
Several of these components, such as lithium chloride or valproic acid, are in clinical use to treat bipolar disorders or epilepsy respectively. They were only recently shown to influence splice-site selection [21, 22] . It is possible that other pharmaceuticals now in clinical use also affect pre-mRNA splicing. Currently, only the use of oligonucleotides allows the unambiguous, specific targeting of a splicing event. This technique is currently being tested for Duchenne's muscular dystrophy and is in the experimental stage for other diseases, such as SMA (spinal muscular atrophy) and thalassemia (reviewed in [23, 24] ).
Substances regulating splice-site selection
Several screens have been performed to find substances that might change the missplicing that is the cause of SMA or that could be a basis for HIV therapy. In addition, a number of individual investigations discovered several substances capable of changing splice-site selection, which are summarized in Table 1 .
HDAC (histone deacetylase) inhibitors
HDAC inhibitors were identified in studies aimed at augmenting the usage of SMN2 (survival of motor neurons 2) exon 7, an outcome that would be a therapeutically valuable approach in the treatment of SMA. These inhibitors include sodium butyrate, valproic acid, sodium 4-phenylbutyrate, M344 and SAHA (suberoylanilide hydroxamic acid) ( Table 1 , numbers 1-5). In mouse models of SMA, these compounds increased the life span of the animals (reviewed in [25] ). Their mechanism of action, however, is not yet clear. Among possible explanations is the role of HDACs. HDACs regulate the chromatin structure and subsequently gene expression by controlling the acetylation state of histones, which in turn determines histone affinity for DNA. It is possible that application of HDAC inhibitors causes a co-ordinated change in the expression of splicing regulatory factors, which in turn dictates a change in splicing. In support of this hypothesis, a change in SR protein (serine/ arginine-rich protein) expression was observed after sodium butyrate application in mice [26] . Another possibility, which has not been systematically investigated, is a direct effect of these substances on the acetylation of splicing-regulatory proteins themselves. Acetylation of SAM68 (68 kDa Srcassociated protein in mitosis), for example, regulates its binding to RNA [14] , and it is possible that other splicing factors are regulated similarly.
Substances that change the phosphorylation state of splicing-regulatory proteins
As mentioned above, reversible phosphorylation is an important mechanism in controlling the selection of alternative exons. As a consequence, kinase and phosphatase inhibitors also affect alternative splice-site selection. The best understood targets for kinases acting on splicing are the SR proteins, a family of highly conserved pre-mRNA splicing factors. SR proteins can bind to each other and the SR domain serves mainly as a protein-protein interaction domain, allowing different SR proteins to oligomerize. This oligomerization is the basis for the formation of exon enhancer complexes. In addition, the SR domain can bind to RNA. It has been shown in several systems that the phosphorylation state of this domain controls the oligomerization of SR proteins that is the basis for the formation of exon-recognition complexes. The phosphorylation state of the SR domain is controlled by the interplay of multiple kinases and phosphatases, located both in the cytosol and the nucleoplasm [12] .
Kinase inhibitors
DNA Topo I (topoisomerase I) effects the phosphorylation of SR proteins [27] and has a dual function in RNA metabolism. It nicks the DNA strand upon transcription, and phosphorylates SR proteins that are known to associate with the nascent pre-mRNA [28] . Numerous antineoplastic drugs that target Topo I were tested for their effect on splice-site selection, and several of them (Table 1 , numbers 6-9) changed splice-site selection.
SR proteins are also phosphorylated by a family of nuclear CDC2 (cell division cycle 2 kinase)-related kinases, termed CLK (CDC-like kinase) 1-4. A specific inhibitor against these kinases, TG003 (Table 1 , number 10), changes alternative splicing in reporter genes [29] and has been tested as an antiviral agent [30] . GSK3 (glycogen synthase kinase 3) also phosphorylates SR proteins, and its inhibition changes alterative splicing of exon 10 of the tau gene [21] (Table 1,  numbers 11 and 12 ). This exon is of medical importance, as mutations causing aberrant usage of the exon leads to frontotemporal dementia (FTDP-17) [31] .
Phosphatase inhibitors
PP1 (protein phosphatase-1) binds directly to a phylogenetically conserved motif in the RNA-recognition motif of at least nine different splicing-regulatory proteins [32] . As a consequence, blocking PP1 activity has a strong influence on alternative splicing. The most specific inhibitor for PP1 is tautomycin, which changes alternative splicing in cell culture and mouse models [32] . Similar effects were seen for cantharidin, which inhibits both PP1 and PP2A (protein phosphatase-2A) ( Table 1 , numbers 13-16). Ceramides activate PP1 by an unknown mechanism that probably involves dissociation of the phosphatase from its inhibitors. C 6 -ceramide, shown in Table 1 [14] , has been shown to change splice-site selection in some apoptotic genes. The change in alternative splicing of genes involved in apoptosis explains the cytotoxic effect of these drugs that are used in chemotherapy [33] .
In vivo, PP1 is blocked by specific protein inhibitors, Inhibitor-1 and DARPP-32 (dopamine-and cAMP-regulated phosphoprotein of 32 kDa), which are activated by phosphorylation by PKA (protein kinase A). Since PKA is activated by a rise in cellular cAMP levels, cAMP increase leads to a decrease in PP1 activity, which has an effect on splice-site selection. This mechanistic link explains the actions of salbutamol [34] (a β 2 -adrenergic agonist) and indoprofen [35] (a compound that blocks cyclo-oxygenase and phosphodiesterase) on splicing ( Table 1 , numbers 17 and 18).
Steroid hormones
The selection of alternative exons is coupled with promoter usage, as the C-terminal domain of polymerase II interacts with components of the splicing machinery. This outcome explains why alternative splicing events can be controlled by steroid hormones when their pre-mRNA transcription is controlled by steroid-responsive promoters [36] . In addition, CAPER [co-activator of AP-1 (activator protein-1) and ER (oestrogen receptor)] proteins have been identified that are activated by steroid hormones and act on both transcription and splicing [37] (Table 1 , numbers 20 and 21).
Protein-protein interaction
The interaction between SR proteins can be interrupted by isoquinolines, which target specific members of this class of proteins. These findings can be applied in vitro to block HIV replication [38, 39] (Table 1 , number 19).
Ion channels
Alternative splicing events change in response to neuronal stimulation [11, 40] . Several compounds, including valproic acid, glutamate and EIPA [5-(N-ethyl) -N-isopropylamiloride], affect splicing in cell culture. However, the exact mechanism that links this change in membrane properties to the splicing machinery remains unclear (Table 1, numbers 23  and 24 ).
Other components
Still other investigations identified a group of apparently unrelated compounds that affect alternative splicing. The mechanism of action of these compounds remains unclear (Table 1, numbers 25-32) .
Future developments
The compounds in Table 1 clearly underscore the dramatic ability of small molecules to affect alternative splicing decisions. Their discovery raises the prospect for finding still other natural, synthetic or semi-synthetic compounds that will directly interact with the spliceosome components or will indirectly alter signal transduction pathways that regulate splice-site selection. Finding substances that possess specificity for a single splicing event or for a certain step in the splicing process represents a future challenge that, once solved, will allow us to understand the fundamental aspects of this intriguing process and to treat human diseases caused by missplicing events. 
